Protein family linked to autism suppresses the development of inhibitory synapses

January 28, 2013, Rockefeller University
A JCB study reveals that a neuronal protein linked to neurodevelopmental disorders suppresses the development of inhibitory synapses. MDGA1 disrupts the interaction between neuroligin-2 and neurexin-1, two synaptic cell adhesion molecules associated with autism and schizophrenia that promote inhibitory synapse development. In this co-culture assay, a neuron forms multiple presynapses (red) with a COS7 cell (right) expressing neuroligin-2 (blue) but only a few presynapses with a cell (left) coexpressing neuroligin-2 and MDGA1 (green). Credit: Pettem, K.L., et al. 2013. J. Cell Biol. doi:10.1083/jcb.201206028

Synapse development is promoted by a variety of cell adhesion molecules that connect neurons and organize synaptic proteins. Many of these adhesion molecules are linked to neurodevelopmental disorders; mutations in neuroligin and neurexin proteins, for example, are associated with autism and schizophrenia. According to a study in The Journal of Cell Biology, another family of proteins linked to these disorders regulates the function of neuroligins and neurexins in order to suppress the development of inhibitory synapses.

Like neurexins and neuroligins, the neuronal proteins MDGA1 and MDGA2 have been linked to autism and schizophrenia, but their function in neurodevelopment was unknown. Both MDGA proteins localize to the , and their extracellular domains are similar to those of cell adhesion molecules. On the other hand, postsynaptic neuroligin proteins are known to help synapses form by associating with neurexins on presynaptic membranes. Neuroligin-2 specifically boosts the development of , whereas neuroligin-1 promotes the development of excitatory synapses.

Ann Marie Craig and colleagues from the University of British Columbia investigated the function of MDGAs using co-culture assays, in which postsynaptic proteins like neuroligin-1 or -2 are expressed in non- and then tested for their ability to induce presynaptic differentiation in neighboring . MDGA1 didn't promote synapse formation in these assays. Instead, it inhibited the ability of neuroligin-2 to promote synapse development. The researchers found that MDGA1's extracellular domains bound to neuroligin-2, blocking its association with . The same domains were sufficient to inhibit neuroligin-2's synapse-promoting activity. In contrast, MDGA1 didn't show high affinity binding to, or inhibit the function of, neuroligin-1. This suggested that, by inhibiting neuroligin-2, MDGA1 might specifically suppress the development of inhibitory synapses, so Craig and colleagues investigated MDGA1 function in cultured hippocampal neurons.

"Overexpressing MDGA1 in neurons reduced the density of inhibitory synapses without affecting excitatory synapses," Craig says. Knocking down MDGA1, on the other hand, increased inhibitory synapse development but had no effect on .

"I can't think of any other proteins that specifically suppress inhibitory synapse formation," says Craig. Indeed, very few proteins in general have been identified as negative regulators of synapse development, compared to the many proteins that are known to promote synaptogenesis. The results suggest that function-altering mutations in the MDGA proteins may disrupt the balance of excitatory and inhibitory synapses in the brain, potentially explaining the development of autism and other neurodevelopmental disorders.

"This puts MDGAs in the same pathway as neurexins and neuroligins and strengthens the evidence for the involvement of synaptic organizing proteins in autism and schizophrenia," Craig explains. As well as investigating the function of MDGA2, the researchers want to explore the therapeutic potential of MDGA1 inhibitors, not only against autism and but also for the treatment of epilepsy, in which excitatory and inhibitory synapses are also imbalanced

Explore further: Balancing connections for proper brain function

More information: Pettem, K.L., et al. 2013. J. Cell Biol. doi:10.1083/jcb.201206028

Related Stories

Balancing connections for proper brain function

June 22, 2012
Neuropsychiatric conditions such as autism, schizophrenia and epilepsy involve an imbalance between two types of synapses in the brain: excitatory synapses that release the neurotransmitter glutamate, and inhibitory synapses ...

Recommended for you

Researchers illustrate how muscle growth inhibitor is activated, could aid in treating ALS

January 19, 2018
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for ...

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.